Skip to main content

Long-term effect of intravenous immunoglobulin on anti-MuSK antibody-positive myasthenia gravis

Buy Article:

$43.00 plus tax (Refund Policy)

Shibata-Hamaguchi A, Samuraki M, Furui E, Iwasa K, Yoshikawa H, Hayashi S, Yamada M. Long-term effect of intravenous immunoglobulin on anti-MuSK antibody-positive myasthenia gravis.

Acta Neurol Scand 2007: 116: 406–408.

© 2007 The Authors Journal compilation © 2007 Blackwell Munksgaard.

Anti-muscle-specific receptor tyrosine kinase (MuSK) antibody-positive myasthenia gravis (MG) patients show various responses to conventional immunosuppressive treatment and some patients are resistant to these therapies. We report a 50-year-old Japanese man with anti-MuSK antibody-positive MG, who showed no or poor response to various therapies, including plasmapheresis, corticosteroid, and tacrolimus. The patient was then treated with intravenous immunoglobulin (IVIG), and showed a good response that persisted over 20 months. The outcome of this case suggests that IVIG treatment may be an effective therapeutic option for anti-MuSK antibody-positive MG, with a potentially long-term effect.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: anti-MuSK antibody; intravenous immunoglobulin; myasthenia gravis; treatment

Document Type: Research Article

Affiliations: 1: Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Science, Ishikawa, Japan 2: Department of Neurology, Toyama City Hospital, Toyama, Japan

Publication date: 2007-12-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more